Multiple Sclerosis Ofatumumab

Ofatumumab (Ofatumumab) is a fully human anti-CD20 monoclonal antibody that can be self-administered by patients and is approved in many countries around the world for the treatment of relapsing multiple sclerosis (RMS). Multiple sclerosis is an incurable disease, and the monoclonal antibody ofatumumab promotes the development and progression of multiple sclerosis by reducing B cell levels.

In two identical Phase III trials in adults with relapsing forms of multiple sclerosis, subcutaneous injections of teriflunomide were more effective than oral teriflunomide in reducing annual relapse rates, reducing MRI-detected lesion activity and limiting worsening of disability. Multiple sclerosis tolerability was generally manageable; the most common adverse events (AEs) included nasopharyngitis, headache, upper respiratory tract infection, and urinary tract infection. Adverse events of particular concern include infections and injection-related reactions, which are generally manageable. After 3.5 years of MS treatment, there was no clear link between changes in immunoglobulin G or M levels and the risk of serious infection. Therefore, MS is a convenient and effective treatment with manageable tolerability in adults with relapsing forms of MS.

The original drug of ofatumumab has been launched in China and has also been included in medical insurance. Only patients who meet the indications can be reimbursed. The price is around tens of thousands of yuan, and domestic purchase channels are relatively difficult. The European version of ofatumumab original drug specifications20mg/0.4mL each sold overseas may cost around RMB 16,000 (the price may fluctuate due to the exchange rate). It is expensive and there are currently no generics of ofatumumab. For more drug information and specific prices, please consult a medical consultant.